Foundayo
The latest news about Foundayo: headlines, AI summaries and the full story from every source.
- Eli Lilly Announces Promising Weight Loss Drug Combination
- Eli Lilly Halts Development of an Obesity Drug Amid High Standards and Strategic Diversification
- Novo Nordisk outlines growth strategy amid Eli Lilly's expanding GLP-1 lead
- Eli Lilly's Foundayo Gains Rapid Market Share in Oral Weight-Loss Segment
- Eli Lilly Captures Over 30% of New U.S. Patients on Oral Weight-Loss Medications
- Rising Use of GLP-1 Drugs Benefits Eli Lilly
- Eli Lilly Shares Reach Record High Amid Regulatory and Market Developments
- Eli Lilly Reports Weight Loss Results Across Menopause Stages in Obesity Drug Trial
- Eli Lilly's Continued Growth Driven by GLP-1 Expansion and Strategic Acquisitions
- Eli Lilly CEO's Comments on Foundayo Spark Optimism Among Investors
- Eli Lilly Achieves Coverage of All Obesity Medicines by Major U.S. Pharmacy Benefit Managers
- Eli Lilly CEO Comments on Foundayo Spark Optimism Among Investors
- Novo Nordisk Faces Pricing Pressure Amid Strong Demand and Competition from Eli Lilly
- Eli Lilly's Volatile Trading Day Amid FDA Safety Concerns and Market Uncertainty
- Truist Reaffirms Buy Rating on Eli Lilly Following Positive Trial Results for Foundayo
- Novo Nordisk's Wegovy Pill Boosts GLP-1 Market, Challenges Eli Lilly's Position
- Eli Lilly Reports Strong Earnings Growth Driven by Weight Loss Drugs
- Eli Lilly Raises Annual Profit Forecast Due to Strong Demand for GLP-1 Drugs
- Eli Lilly to Report First-Quarter Earnings Ahead of Market Open
- Eli Lilly Investors Await Foundayo Launch Data Amid Market Uncertainty
- Eli Lilly's Stock Declines Due to Slower Than Expected Sales of New Weight Loss Drug
- Eli Lilly Shares Drop on Foundayo's Weak Performance; FDA Issues Psychedelic Vouchers
- Eli Lilly Receives FDA Request for Additional Data on Obesity Pill
- Eli Lilly's Obesity Pill Shows Strong Initial Performance; OpenAI Launches New Drug Discovery AI Tool
- Eli Lilly's Weight Loss Pill Prescriptions Reach 1,390 in First Week of Sales
- Eli Lilly's Obesity Pill Shows Cardiovascular Risk Reduction in Late-Stage Trial
- Eli Lilly Required to Conduct Post-Marketing Studies for Obesity Drug Foundayo